Published in Clin Med on March 12, 2007
CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity (2010) 5.13
Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum (2006) 3.11
Novel suppressive function of transitional 2 B cells in experimental arthritis. J Immunol (2007) 3.09
Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum (2003) 3.00
The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice. Proc Natl Acad Sci U S A (2002) 2.72
An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum (2002) 2.54
Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med (2007) 2.47
The 'short' history of regulatory B cells. Trends Immunol (2007) 2.38
Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells. J Immunol (2011) 2.31
CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. Sci Transl Med (2013) 1.89
Impact of DNA ligase IV on nonhomologous end joining pathways during class switch recombination in human cells. J Exp Med (2005) 1.84
Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc Natl Acad Sci U S A (2008) 1.69
Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation (2009) 1.61
The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. Rheumatology (Oxford) (2011) 1.55
Germinal center B cells govern their own fate via antibody feedback. J Exp Med (2013) 1.36
Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis. Proc Natl Acad Sci U S A (2009) 1.34
Predominant role of IgM-dependent activation of the classical pathway in the clearance of dying cells by murine bone marrow-derived macrophages in vitro. Eur J Immunol (2005) 1.29
Natural IgM is required for suppression of inflammatory arthritis by apoptotic cells. J Immunol (2011) 1.14
Regulatory T-cells in systemic lupus erythematosus and rheumatoid arthritis. FEBS Lett (2011) 1.09
Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigen-specific regulatory T cells, and suppresses experimental inflammatory arthritis. Arthritis Rheum (2011) 1.08
Statins for atherosclerosis--as good as it gets? N Engl J Med (2005) 1.08
Atorvastatin restores Lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus. J Immunol (2006) 1.08
Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy. Arthritis Rheum (2012) 1.07
Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice. J Immunol (2004) 1.02
Natural serum IgM maintains immunological homeostasis and prevents autoimmunity. Springer Semin Immunopathol (2004) 1.00
Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum (2013) 0.98
Increased positive selection of B1 cells and reduced B cell tolerance to intracellular antigens in c1q-deficient mice. J Immunol (2007) 0.96
Cutting edge: selection of B lymphocyte subsets is regulated by natural IgM. J Immunol (2002) 0.94
The yin and yang of regulatory T cells and inflammation in RA. Nat Rev Rheumatol (2010) 0.92
Abnormal CTLA-4 function in T cells from patients with systemic lupus erythematosus. Eur J Immunol (2010) 0.91
Restoring the balance: harnessing regulatory T cells for therapy in rheumatoid arthritis. Eur J Immunol (2008) 0.90
Regulatory T-cell adoptive immunotherapy: potential for treatment of autoimmunity. Expert Rev Clin Immunol (2011) 0.88
Secreted IgM enhances B cell receptor signaling and promotes splenic but impairs peritoneal B cell survival. J Immunol (2010) 0.87
Cells of the synovium in rheumatoid arthritis. B cells. Arthritis Res Ther (2007) 0.85
B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels. Rheumatology (Oxford) (2012) 0.85
Tuberculosis and anti-TNF treatment: experience of a central London hospital. Clin Rheumatol (2010) 0.84
Induced CD8+FoxP3+ Treg cells in rheumatoid arthritis are modulated by p38 phosphorylation and monocytes expressing membrane tumor necrosis factor α and CD86. Arthritis Rheumatol (2014) 0.79
Therapeutic potential of Tregs to treat rheumatoid arthritis. Semin Immunol (2011) 0.78
Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales: addressing treatment outside the current NICE guidance. Clin Rheumatol (2012) 0.75